4-ethoxy-3-fluorobenzoic acid | 5710-64-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-ethoxy-3-fluorobenzoic acid
• CAS: 5710-64-5
• 化学式: C₉H₉FO₃
• 分子量: 184.167
• InChiKey: PRBYLMBZCTVHIP-UHFFFAOYSA-N

物化性质

• 熔点：
  176 °C
• 沸点：
  298.8±20.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-ethoxy-3-fluorobenzoic acid 在 吡啶 、 氯化亚砜 作用下， 以 苯 为溶剂， 生成 4-Aethoxy-3-fluor-benzoesaeure-<2-dimethylamino-aethylester>
  参考文献：
  名称：

  Maziere; Maziere; Dat-Xuong, Bulletin de la Societe Chimique de France, 1965, vol. 12, p. 3494 - 3500

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氟苯酚 在 溴 、 叔丁基锂 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 、 正戊烷 为溶剂， 反应 48.25h， 生成 4-ethoxy-3-fluorobenzoic acid
  参考文献：
  名称：

  Potent, Novel in Vitro Inhibitors of the Pseudomonas aeruginosa Deacetylase LpxC

  摘要：

  Deacetylation of uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine by LpxC is the first committed step in the Pseudomonas aeruginosa biosynthetic pathway to lipid A; homologous enzymes are found widely among Gram-negative bacteria. As an essential enzyme for which no inhibitors have yet been reported, the P. aeruginosa LpxC represents a highly attractive target for a novel antibacterial drug. We synthesized several focused small-molecule libraries, each composed of a variable aromatic ring, one of four heterocyclic/spacer moieties, and a hydroxamic acid and evaluated the LpxC inhibition of these compounds against purified P. aeruginosa enzyme. To ensure that the in vitro assay would be as physiologically relevant as possible, we synthesized a tritiated form of the specific P. aeruginosa glycolipid substrate and measured directly the enzymatically released acetate. Several of our novel compounds, predominantly those having fluorinated substituents on the aromatic ring and an oxazoline as the heterocyclic moiety, demonstrated in vitro IC50 values less than 1 muM. We now report the synthesis and in vitro evaluation of these P. aeruginosa LpxC inhibitors.

  DOI：

  10.1021/jm010579r

文献信息

• [EN] TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS D'ACIDE TÉTRAHYDROCYCLOPENTA[B]INDOL-3-YLCARBOXYLIQUE UTILES DANS LE TRAITEMENT DE TROUBLES AUTO-IMMUNS ET INFLAMMATOIRES
  申请人：ARENA PHARM INC

  公开号：WO2009078983A1

  公开（公告）日：2009-06-25

  The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

  本发明涉及公式（Ia）中的某些（1,2,4-噁二唑-3-基）-1,2,3,4-四氢环-五氢-苯并[b]吲哚-3-基羧酸衍生物及其药学上可接受的盐，该衍生物具有有用的药理特性，例如作为S1P1受体的激动剂。本发明还提供了含有所述化合物的药物组合物，以及使用所述化合物和组合物治疗S1P1相关疾病的方法，例如银屑病、类风湿性关节炎、克罗恩病、移植排斥反应、多发性硬化症、系统性红斑狼疮、溃疡性结肠炎、I型糖尿病、痤疮、微生物感染或疾病以及病毒感染或疾病。
• Synthesis and Mesomorphic Properties of Novel Bent-shaped Naphthyl Diketones
  作者：Anđela Buljan、Anamarija Knežević、Irena Dokli、Andreja Lesac

  DOI：10.5562/cca3541

  日期：——

  The synthesis and liquid-crystalline properties are reported for novel naphthyl-based diketones incorporating variant terminal chains and lateral fluoro- substitution. Newly prepared materials exhibit a broad temperature range of the nematic phase. The study demonstrates how subtle structural modifications can be exploited to alter the efficiency of molecular packing and consequently the thermal behaviour.

  报道了一种新型基于萘的二酮，其包含不同的末端链和侧基氟取代，具有液晶性能。新制备的材料展示了广泛的向列相温度范围。该研究表明，微小的结构修饰可以被利用来改变分子堆积的效率，从而改变热行为。
• TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
  申请人：Jones Robert M.

  公开号：US20100273806A1

  公开（公告）日：2010-10-28

  The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

  本发明涉及公式(Ia)的某些(1,2,4-噁二唑-3-基)-1,2,3,4-四氢环戊[b]吲哚-3-基羧酸衍生物及其药学上可接受的盐，其具有有用的药理特性，例如作为S1P1受体的激动剂。本发明还提供了含有本发明化合物的药物组合物以及使用本发明化合物和组合物治疗S1P1相关疾病的方法，例如牛皮癣、类风湿性关节炎、克隆病、移植排斥反应、多发性硬化症、系统性红斑狼疮、溃疡性结肠炎、1型糖尿病、痤疮、微生物感染或疾病和病毒感染或疾病。
• <i>N</i>-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy
  作者：George Amato、Rosemarie Roeloffs、Greg C. Rigdon、Brett Antonio、Theresa Mersch、Grant McNaughton-Smith、Alan D. Wickenden、Paul Fritch、Mark J. Suto

  DOI：10.1021/ml200053x

  日期：2011.6.9

  A series of N-pyridyl benzamide KCNQ2/Q3 potassium channel openers were identified and found to be active in animal models of epilepsy and pain. The best compound 12 [ICA-027243, N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide] has an EC(50) of 0.38 mu M and is selective for KCNQ2/Q3 channels. This compound was active in several rodent models of epilepsy and pain but upon repeated dosing had a number of unacceptable toxicities that prevented further development. On the basis of the structure activity relationships developed around 12, a second compound, 51, [N-(2-chloro-pyrimidin-5-yl)-3,4-difluoro-benzamide, ICA-069673], was prepared and advanced into a phase 1 clinical study. Herein, we describe the structure activity relationships that led to the identification of compound 12 and to the corresponding pyrimidine 51.
• TRICYCLIC CARBOXAMIDES
  申请人：SmithKline Beecham plc

  公开号：EP1102769B1

  公开（公告）日：2003-04-16